Literature DB >> 20063426

Irinotecan as maintenance therapy in high-risk hepatoblastoma.

Muna Qayed1, Christie Powell, Elaine R Morgan, Maureen Haugen, Howard M Katzenstein.   

Abstract

Children with high-risk hepatoblastoma (metastatic disease or a low alpha-fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1- to 2-year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high-risk and recurrent HB patients is warranted.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20063426     DOI： 10.1002/pbc.22408

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  7 in total

1.  Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.

Authors:  Tomoro Hishiki; Tadashi Matsunaga; Fumiaki Sasaki; Michihiro Yano; Kohmei Ida; Hiroshi Horie; Satoshi Kondo; Ken-Ichiro Watanabe; Takaharu Oue; Tatsuro Tajiri; Arata Kamimatsuse; Naomi Ohnuma; Eiso Hiyama
Journal:  Pediatr Surg Int       Date:  2011-01       Impact factor: 1.827

2.  Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.

Authors:  R C Brennan; W Furman; S Mao; J Wu; D C Turner; C F Stewart; V Santana; L M McGregor
Journal:  Cancer Chemother Pharmacol       Date:  2014-09-26       Impact factor: 3.333

3.  Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.

Authors:  Howard M Katzenstein; Wayne L Furman; Marcio H Malogolowkin; Mark D Krailo; M Beth McCarville; Alexander J Towbin; Greg M Tiao; Milton J Finegold; Sarangarajan Ranganathan; Stephen P Dunn; Max R Langham; Eugene D McGahren; Carlos Rodriguez-Galindo; Rebecka L Meyers
Journal:  Cancer       Date:  2017-02-17       Impact factor: 6.860

Review 4.  Current and future management strategies for relapsed or progressive hepatoblastoma.

Authors:  Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

5.  A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Authors:  Wayne L Furman; Lisa M McGregor; M Beth McCarville; Mihaela Onciu; Andrew M Davidoff; Sandy Kovach; Dana Hawkins; Valerie McPherson; Peter J Houghton; Catherine A Billups; Jianrong Wu; Clinton F Stewart; Victor M Santana
Journal:  Invest New Drugs       Date:  2011-07-28       Impact factor: 3.850

6.  Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.

Authors:  Allison F O'Neill; Alexander J Towbin; Mark D Krailo; Caihong Xia; Yun Gao; M Beth McCarville; Rebecka L Meyers; Eugene D McGahren; Greg M Tiao; Stephen P Dunn; Max R Langham; Christopher B Weldon; Milton J Finegold; Sarangarajan Ranganathan; Wayne L Furman; Marcio Malogolowkin; Carlos Rodriguez-Galindo; Howard M Katzenstein
Journal:  J Clin Oncol       Date:  2017-09-11       Impact factor: 44.544

7.  Hepatoblastoma: Analysis of treatment outcome from a tertiary care center.

Authors:  Sanju Cyriac; Ramakrishnan Ayloor Seshadri; Arun Warrier; Tenali Gnana Sagar
Journal:  J Indian Assoc Pediatr Surg       Date:  2011-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.